Design, synthesis and in vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer's disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F16%3A43915050" target="_blank" >RIV/00023752:_____/16:43915050 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/60162694:G44__/16:43875619 RIV/62690094:18470/16:50004736 RIV/00216208:11160/16:10324912 RIV/00179906:_____/16:10324912
Výsledek na webu
<a href="http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201500383/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201500383/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/cmdc.201500383" target="_blank" >10.1002/cmdc.201500383</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Design, synthesis and in vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer's disease
Popis výsledku v původním jazyce
Novel indolotacrine analogues were designed, synthesized, and evaluated as potential drugs for the treatment of Alzheimer's disease. By using a multitarget-directed ligand approach, compounds were designed to act simultaneously as cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors. The compounds were also evaluated for antioxidant, cytotoxic, hepatotoxic, and blood-brain barrier (BBB) permeability properties. Indolotacrine 9b (9-methoxy-2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-amine) showed the most promising results in the in vitro assessment; it is a potent inhibitor of acetylcholinesterase (AChE IC50: 1.5 mu m), butyrylcholinesterase (BChE IC50: 2.4 mu m) and MAO A (IC50: 0.49 mu m), and it is also a weak inhibitor of MAO B (IC50: 53.9 mu m). Although its cytotoxic (IC50: 5.5 +/- 0.4 mu m) and hepatotoxic (IC50: 1.22 +/- 0.11 mu m) profiles are not as good as those of the standard 7-methoxytacrine (IC50: 63 +/- 4 and 11.50 +/- 0.77 mu m, respectively), the overall improvement in the inhibitory activities and potential to cross the BBB make indolotacrine 9b a promising lead compound for further development and investigation.
Název v anglickém jazyce
Design, synthesis and in vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer's disease
Popis výsledku anglicky
Novel indolotacrine analogues were designed, synthesized, and evaluated as potential drugs for the treatment of Alzheimer's disease. By using a multitarget-directed ligand approach, compounds were designed to act simultaneously as cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors. The compounds were also evaluated for antioxidant, cytotoxic, hepatotoxic, and blood-brain barrier (BBB) permeability properties. Indolotacrine 9b (9-methoxy-2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-amine) showed the most promising results in the in vitro assessment; it is a potent inhibitor of acetylcholinesterase (AChE IC50: 1.5 mu m), butyrylcholinesterase (BChE IC50: 2.4 mu m) and MAO A (IC50: 0.49 mu m), and it is also a weak inhibitor of MAO B (IC50: 53.9 mu m). Although its cytotoxic (IC50: 5.5 +/- 0.4 mu m) and hepatotoxic (IC50: 1.22 +/- 0.11 mu m) profiles are not as good as those of the standard 7-methoxytacrine (IC50: 63 +/- 4 and 11.50 +/- 0.77 mu m, respectively), the overall improvement in the inhibitory activities and potential to cross the BBB make indolotacrine 9b a promising lead compound for further development and investigation.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ChemMedChem
ISSN
1860-7179
e-ISSN
—
Svazek periodika
11
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
6
Strana od-do
1264-1269
Kód UT WoS článku
000380024300010
EID výsledku v databázi Scopus
2-s2.0-84978757630